Esperion Therapeutics acquired by Essence Parent for $3.16 per share plus contingent payments
Essence Parent Inc. completed its acquisition of Esperion Therapeutics on July 13, 2026, with shareholders receiving $3.16 per share in cash plus one contingent value right per share representing the right to participate in contingent payments of up to $100 million in the aggregate upon achievement of specified milestones. The aggregate consideration paid was approximately $1.1 billion in cash plus the issuance of CVRs. The company's common stock will be delisted from Nasdaq.
Key facts
- Merger consideration: $3.16 per share in cash plus one CVR per share
- Contingent value rights: up to $100 million in aggregate upon achievement of specified milestones
- Aggregate consideration: approximately $1.1 billion in cash plus CVRs
- Bempedoic Acid Milestone: $40 million if annual Net Sales exceed $350 million in 2027, or pro-rata between $0–$40 million if sales are $300–$350 million
- Enbumyst Milestone: $60 million if annual Net Sales reach $160 million in any year through 2030
- Effective Time: July 13, 2026
- CVRs non-transferable except in limited circumstances; represent contractual rights only
- Company becomes wholly owned subsidiary of Essence Parent Inc.
- Stock delisting from Nasdaq; Form 15 termination of reporting obligations intended
Why it matters
The acquisition marks the end of Esperion's independence as a public company, with shareholders receiving both immediate cash and contingent payments tied to future sales milestones for bempedoic acid and bumetanide products; the structure preserves upside for equity holders tied to product commercialization success.
Share
Derived from 8-K filed 2026-07-13. Not investment advice. View the source filing on SEC.gov →